Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality, HCQ vs. non-.. 71% Improvement Relative Risk Mortality, HCQ+X vs. X 71% Improvement by 2 points 4% Viral clearance 10% HCQ  PROTECT  EARLY TREATMENT  RCT Is early treatment with HCQ beneficial for COVID-19? RCT 471 patients in Pakistan Trial compares with azithromycin and oseltamivir Lower mortality with HCQ (p=0.028) c19hcq.org Azhar et al., Pakistan J. Medical Scie.., Mar 2024 Favors HCQ Favors azithromycin..

Effectiveness of early pharmaceutical interventions in symptomatic COVID-19 patients: A randomized clinical trial

Azhar et al., Pakistan Journal of Medical Sciences, doi:10.12669/pjms.40.5.8757, PROTECT, NCT04338698
Mar 2024  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
RCT 471 mild COVID-19 patients in Pakistan showing no significant differences in clinical improvement and viral clearance between HCQ, azithromycin, oseltamivir, and combinations. Mortality was significantly lower in HCQ vs. non-HCQ arms. The best results for viral clearance and clinical improvement were seen with the combination of all treatments. There was no control group. No serious adverse events were reported. All patients had mild COVID-19 and the paper indicates early treatment, however time from onset is not reported and minimal baseline information is provided.
risk of death, 71.3% lower, RR 0.29, p = 0.03, treatment 4 of 248 (1.6%), control 10 of 178 (5.6%), NNT 25, HCQ arms vs. non-HCQ arms.
risk of death, 70.8% lower, RR 0.29, p = 0.05, treatment 3 of 183 (1.6%), control 10 of 178 (5.6%), NNT 25, HCQ + OS/AZ/OS+AZ vs. OS/AZ/OS+AZ.
risk of no improvement by 2 points, 4.3% lower, RR 0.96, p = 0.64, treatment 157 of 274 (57.3%), control 118 of 197 (59.9%), NNT 38, HCQ arms vs. non-HCQ arms.
risk of no viral clearance, 10.5% lower, RR 0.90, p = 0.52, treatment 66 of 274 (24.1%), control 53 of 197 (26.9%), NNT 36, HCQ arms vs. non-HCQ arms.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Azhar et al., 18 Mar 2024, Randomized Controlled Trial, Pakistan, peer-reviewed, 22 authors, dosage 200mg tid days 1-5, this trial compares with another treatment - results may be better when compared to placebo, trial NCT04338698 (history) (PROTECT).
This PaperHCQAll
Effectiveness of early pharmaceutical interventions in symptomatic COVID-19 patients: A randomized clinical trial
Shehnoor Azhar, Javed Akram, Waqas Latif, Naomi Cano Ibanez, Samiullah Mumtaz, Ali Rafi, Usman Aftab, Somia Iqtadar, Muhammad Shahzad, Fibhaa Syed, Bilal Zafar, Nighat Fatima, Saleh Saadat Afridi, Shehla Javed Akram, Muhammad Afzal Chaudhary, Farah Sadiq, Saifullah Goraya, Muhammad Hanif, Verda Ashraf, Saadia Ashraf, Humaira Akram, Tanwir Khaliq
doi:10.12669/pjms.40.5.8757
Objective: We assessed the effectiveness of oral Hydroxychloroquine (HC), Azithromycin (AZ) and Oseltamivir (OS), alone or combined, among patients hospitalized with mildly symptomatic coronavirus infectious disease (COVID-19). Methods: Following the approval of the National Bioethics Committee and prospective registration (clinicaltrials.gov NCT04338698), a multicenter randomized clinical trial of adaptive design was conducted at 10 multispecialty hospitals in Pakistan. Patients were randomized into seven treatment groups. Starting April 15, 2020, consenting, eligible, otherwise healthy adult patients or those with co-morbidities under control, were recruited if they presented with mildly symptomatic COVID-19 (scored 3 on a 7-point ordinal scale anchored between 1 = not hospitalized, able to undertake normal activities, to 7 = death) confirmed by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). Two primary outcomes were assessed by day seven: Turning qRT-PCR negative; and clinical improvement of two points from the baseline. Outcome rates were compared using a chi-square test. Multiple imputations were applied to handle missing data. An interim data analysis was carried out on July 19, 2020, following which the study continued without treatment group changes. Data Safety and Monitoring Board advised to stop recruitment due to its futility on January 18, 2021. Results: Of 471 patients randomized, a total of 426 (90.4%) completed the follow-up for primary outcomes. Based on imputed data analyses at day seven: Total qRT-PCR negative cases were 137/471 (29%, 95% CI 25.0 -33.4). By day seven, a total of 111/471 (23.5%, 95% CI 19.8 -27.6) showed clinical improvement. No serious or non-serious adverse event was reported. Conclusions: Among patients with mild COVID-19, there was no statistically significant difference in the effectiveness of oral antimalarial, antiviral, or antibiotic treatments.
References
Abduljabbar, Alghamdi, Althobaiti, Althubaiti, Alharthi et al., The length of hospital stays and clinical and therapeutic characteristics of patients with COVID-19 early in the pandemic in Taif City, KSA: A retrospective study, Medicine (Baltimore), doi:10.1097/MD.0000000000032386
Aftab, None
Afzal, None
Akram, Azhar, Shahzad, Latif, Khan, Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial, Trials, doi:10.1186/s13063-020-04616-4
Akram, Mbbs, Frcp, None
Akram, None
Angus, Berry, Lewis, Al-Beidh, Arabi et al., The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design, Ann Am Thorac Soc, doi:10.1513/AnnalsATS.202003-192SD
Aranda, Loureiro-Amigo, Murgadella, Vazquez, Feria et al., Changing Trends in the Global Consumption of Treatments Used in Hospitalized Patients for COVID-19: A Time Series Multicentre Study, Antibiotics, doi:10.3390/antibiotics12050809
Ashraf, None
Ashraf, None
Axfors, Schmitt, Janiaud, Van't Hooft, Abd-Elsalam et al., Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative metaanalysis of randomized trials, Nat Commun, doi:10.1038/s41467-021-22446-z
Azhar, Akram, Shahzad, Latif, Khan, Protocol of Pakistan randomized and observational trial to evaluate coronavirus treatment among newly diagnosed patients with COVID-19: Azithromycin, Oseltamivir, and Hydroxychloquine, Pak J Med Sci, doi:10.12669/pjms.38.5.5512
Azhar, Bds, Doctoral candidate in Epidemiology and Public Health
Babaei, Mirzababaei, Nassiri-Asl, Hosseinzadeh, Review of registered clinical trials for the treatment of COVID-19, Drug Dev Res, doi:10.1002/ddr.21762
Bhatti, Hospital, ABSTH) Gujrat
Bull-Otterson, Gray, Budnitz, Strosnider, Schieber et al., Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment -United States, January-June 2020, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm6935a4
Burgess, Rennie, Moodley, Key ethical issues encountered during COVID-19 research: a thematic analysis of perspectives from South African research ethics committees, BMC Med Ethics, doi:10.1186/s12910-023-00888-y
Cano, None
Clair, Chan, Paiero, Fraser, Gunvaldsen et al., One Health response to SARS-CoV-2-associated risk from mink farming in British Columbia, Canada, October 2020 to October 2021, Can Commun Dis Rep, doi:10.14745/ccdr.v48i06a04
Curnow, Carpenter, Heron, Cornish, Rach et al., Multiple imputation of missing data under missing at random: compatible imputation models are not sufficient to avoid bias if they are mis-specified, J Clin Epidemiol, doi:10.1016/j.jclinepi.2023.06.011
Dai, Gao, Tao, Hadinegoro, Erkin et al., Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults, N Engl J Med, doi:10.1056/NEJ-Moa2202261
Diallo, Ndejjo, Leye, Egbende, Tusubira et al., Unintended consequences of implementing nonpharmaceutical interventions for the COVID-19 response in Africa: experiences from DRC, Nigeria, Senegal, and Uganda, Global Health, doi:10.1186/s12992-023-00937-6
Dong, Mitani, Multiple imputation methods for missing multilevel ordinal outcomes, BMC Med Res Methodol, doi:10.1186/s12874-023-01909-5
Dunajcik, Haire, Thomas, Moriarty, Springer et al., Travel history among persons infected with SARS-CoV-2 variants of concern in the United States, December 2020-February 2021, PLOS Glob Public Health, doi:10.1371/journal.pgph.0001252
Dutka, Bonello, Integrating a Research Protocol into a Health Care Setting, Nephrol Nurs J
Farlow, Torreele, Gray, Ruxrungtham, Rees et al., The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs, Vaccines, doi:10.3390/vaccines11030690
Fatima, None
Faucheux, Alves, Chevret, Rocha, Comparison of characteristics and laboratory tests of COVID-19 hematological patients from France and Brazil during the pre-vaccination period: identification of prognostic profiles for survival, Hematol Transfus Cell Ther, doi:10.1016/j.htct.2022.05.003
Fricke-Galindo, Valencia, Pharmacogenetics Approach for the Improvement of COVID-19 Treatment, Viruses, doi:10.3390/v13030413
Halperin, Ye, Mackinnon-Cameron, Smith, Cahn et al., Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial, Lancet, doi:10.1016/S0140-6736(21)02753-7
Hanif, None
Hashem, Abufaraj, Tbakhi, Sultan, Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic, Front Med, doi:10.3389/fmed.2020.598038
Hong Nguyen, Ou, Huy, Shih, Chang et al., A global analysis of COVID-19 infection fatality rate and its associated factors during the Delta and Omicron variant periods: an ecological study, Front Public Health, doi:10.3389/fpubh.2023.1145138
Husayn, Brown, Presley, Boghean, Waller, Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic, J Pharm Pract, doi:10.1177/0897190020942658
Iqtadar, None
Jabeen, Rabbani, Telehealth as a public health approach to mitigate the COVID-19 pandemic in Pakistan: A narrative review, J Med Access, doi:10.1177/27550834231181299
Janssen, Schakel, Fokou, Krisam, Stermann et al., A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial, Trials, doi:10.1186/s13063-020-04735-y
Javed Akram, Mbbs, Dtm&h, Dch, None
Khaliq, None, FRCS) Professor of Surgery and Vice Chancellor SZABMU Islamabad
Khan, I. International multistakeholder consensus statement on clinical trial integrity, BJOG, doi:10.1111/1471-0528.17451
Latif, Phil Statistics) Data Analyst
Lauffenburger, Choudhry, Russo, Glynn, Ventz et al., Designing and conducting adaptive trials to evaluate interventions in health services and implementation research: practical considerations, BMJ Med, doi:10.1136/bm-jmed-2022-000158
Mcgarry, Kieburtz, Adaptive clinical trials and master protocols, Handb Clin Neurol, doi:10.1016/B978-0-323-85555-6.00005-9
Medical, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, JAMA, doi:10.1001/jama.2013.281053
Miyazaki, Hosogaya, Fukushige, Takemori, Morimoto et al., A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19, Microbiol Spectr, doi:10.1128/spectrum.04311-22
Mol, Lai, Rahim, Bordewijk, Wang et al., Checklist to assess Trustworthiness in RAndomised Controlled Trials (TRACT checklist): concept proposal and pilot, Res Integr Peer Rev, doi:10.1186/s41073-023-00130-8
Moorthy, Karam, Vannice, Kieny, Rationale for WHO's new position calling for prompt reporting and public disclosure of interventional clinical trial results, PLoS Med, doi:10.1371/journal.pmed.1001819
Mukhopadhyay, Paul, Samanta, Hydroxychloroquine in the prophylaxis of COVID 19: A survey of safety on the healthcare workers in India, Perspect Clin Res, doi:10.4103/picr.PICR_310_20
Mumtaz, None
Munblit, Nicholson, Akrami, Apfelbacher, Chen et al., A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study, Lancet Respir Med, doi:10.1016/S2213-2600(22)00169-2
Murray, Babiker, Baker, Barkauskas, Brown et al., Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3), Clin Trials, doi:10.1177/17407745211049829
Navaei, Taleizadeh, Goodarzian, Designing a new sustainable Test Kit supply chain network utilizing Internet of Things, Eng Appl Artif Intell, doi:10.1016/j.engappai.2023.106585
Quan, Taylor-Robinson, Vietnam's Evolving Healthcare System: Notable Successes and Significant Challenges, Cureus, doi:10.7759/cureus.40414
Rafi, None
Saadat, None
Sadiq, None
Saifullah Goraya, None
Samaras, Bekiaridou, Papazoglou, Moysidis, Tsoumakas et al., Artificial intelligence-based mining of electronic health record data to accelerate the digital transformation of the national cardiovascular ecosystem: design protocol of the Car-dioMining study, BMJ Open, doi:10.1136/bmjo-pen-2022-068698Authors
Shahzad, None
Syed, None
Thorlund, Golchi, Mills, Bayesian adaptive clinical trials of combination treatments, Contemp Clin Trials Commun, doi:10.1016/j.conctc.2017.11.001
Van Kessel, Kyriopoulos, Wong, Mossialos, The Effect of the COVID-19 Pandemic on Digital Health-Seeking Behavior: Big Data Interrupted Time-Series Analysis of Google Trends, J Med Internet Res, doi:10.2196/42401
Yadav, Chowdhury, Effectivity of repurposed drugs against SARS-CoV-2 infections, A hope for COVID 19: inhibitor modelling studies by docking and molecular dynamics, Heliyon, doi:10.1016/j.heliyon.2022.e12327
Zafar, None
Zekarias, Watson, Vidlin, Grundmark, Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports, Drug Saf, doi:10.1007/s40264-020-01000-8
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit